Schubförmig remittierende Multiple Sklerose
G-BA action
discontinuation
2023-07-06
Evidence-checked summary
The G-BA issued a discontinuation on 2023-07-06. The official page states that it took effect as follows: 06.07.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
2022-05-09
64 parsed turns
Oral hearing: Diroximelfumarat (Schubförmig remittierende Multiple Sklerose)
Official Wortprotokoll · 12 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A21-172
matched
Diroximel fumarate (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 42 pages
G-BA decisions
2022-06-16
suspension
The G-BA issued a suspension on 2022-06-16. The official page states that it took effect as follows: mit Beschlussdatum. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
2023-07-06
discontinuation
The G-BA issued a discontinuation on 2023-07-06. The official page states that it took effect as follows: 06.07.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
Official sources